Adaptive Biotechnologies (ADPT) Q3 Earnings: Taking a Look at Key Metrics Versus Estimates

Zacks11-08

For the quarter ended September 2024, Adaptive Biotechnologies (ADPT) reported revenue of $46.44 million, up 22.5% over the same period last year. EPS came in at -$0.22, compared to -$0.35 in the year...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2481193800?lang=en_US&edition=fundamental","thumbnail":"https://s.yimg.com/uu/api/res/1.2/xopQugjeNyS1VO21qlHkcQ--~B/aD02NzU7dz05MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/3cb5117fc22f5e37890d1860dcd61f9f","is_english":true,"pubTime":"2024-11-08 07:30","share_image_url":"https://static.laohu8.com/5f26f4a48f9cb3e29be4d71d3ba8c038","id":"2481193800","market":"us","top_or_hot":-1,"title":"Adaptive Biotechnologies (ADPT) Q3 Earnings: Taking a Look at Key Metrics Versus Estimates","media":"Zacks","content":"<div>\n<p>For the quarter ended September 2024, Adaptive Biotechnologies (ADPT) reported revenue of $46.44 million, up 22.5% over the same period last year. EPS came in at -$0.22, compared to -$0.35 in the year...</p>\n\n<a href=\"https://finance.yahoo.com/news/adaptive-biotechnologies-adpt-q3-earnings-233010442.html\">Source Link</a>\n\n</div>\n","source":"yahoofinance","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Adaptive Biotechnologies (ADPT) Q3 Earnings: Taking a Look at Key Metrics Versus Estimates</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAdaptive Biotechnologies (ADPT) Q3 Earnings: Taking a Look at Key Metrics Versus Estimates\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-11-08 07:30 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://finance.yahoo.com/news/adaptive-biotechnologies-adpt-q3-earnings-233010442.html><strong>Zacks</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>For the quarter ended September 2024, Adaptive Biotechnologies (ADPT) reported revenue of $46.44 million, up 22.5% over the same period last year. EPS came in at -$0.22, compared to -$0.35 in the year...</p>\n\n<a href=\"https://finance.yahoo.com/news/adaptive-biotechnologies-adpt-q3-earnings-233010442.html\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"ADPT","symbol_name":"Adaptive Biotechnologies Corp","start_time":0,"source_url":"https://finance.yahoo.com/news/adaptive-biotechnologies-adpt-q3-earnings-233010442.html","article_id":"2481193800","we_media_id":null,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/xopQugjeNyS1VO21qlHkcQ--~B/aD02NzU7dz05MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/3cb5117fc22f5e37890d1860dcd61f9f"],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2481193800","pubTimestamp":1731022210,"sourceInfo":{"source_id":"yahoofinance","name":"雅虎金融"},"weMediaInfo":null,"summary":"For the quarter ended September 2024, Adaptive Biotechnologies  reported revenue of $46.44 million, up 22.5% over the same period last year. EPS came in at -$0.22, compared to -$0.35 in the year-ago quarter.The reported revenue represents a surprise of +14.41% over the Zacks Consensus Estimate of $40.59 million. With the consensus EPS estimate being -$0.30, the EPS surprise was +26.67%.While investors closely watch year-over-year changes in headline numbers -- revenue and earnings -- and how they compare to Wall Street expectations to determine their next course of action, some key metrics always provide a better insight into a company's underlying performance.As these metrics influence top- and bottom-line performance, comparing them to the year-ago numbers and what analysts estimated helps investors project a stock's price performance more accurately.Here is how Adaptive Biotechnologies performed in the just reported quarter in terms of the metrics most widely monitored and projected","collect":0,"end_time":0,"defaultTopTitle":"yahoo.com","property":["earning"],"viewcount":null,"language":"en","relate_stocks":{"ADPT":"Adaptive Biotechnologies Corp"},"translate_title":"Adaptive Biotechnologies(ADPT)第三季度收益：看看关键指标与预期","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"ADPT":1},"content_text":"For the quarter ended September 2024, Adaptive Biotechnologies (ADPT) reported revenue of $46.44 million, up 22.5% over the same period last year. EPS came in at -$0.22, compared to -$0.35 in the year-ago quarter.\nThe reported revenue represents a surprise of +14.41% over the Zacks Consensus Estimate of $40.59 million. With the consensus EPS estimate being -$0.30, the EPS surprise was +26.67%.\nWhile investors closely watch year-over-year changes in headline numbers -- revenue and earnings -- and how they compare to Wall Street expectations to determine their next course of action, some key metrics always provide a better insight into a company's underlying performance.\nAs these metrics influence top- and bottom-line performance, comparing them to the year-ago numbers and what analysts estimated helps investors project a stock's price performance more accurately.\nHere is how Adaptive Biotechnologies performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts: \n\nClonoSEQ test volume: 19,600 compared to the 19,534 average estimate based on three analysts.\nRevenues- Total MRD: $37.47 million versus the three-analyst average estimate of $33.56 million. The reported number represents a year-over-year change of +51.9%.\nRevenues- Total Immune Medicine: $8.97 million compared to the $6.74 million average estimate based on three analysts. The reported number represents a change of -32.3% year over year.\n View all Key Company Metrics for Adaptive Biotechnologies here>>>\n\nShares of Adaptive Biotechnologies have returned +15% over the past month versus the Zacks S&P 500 composite's +3.2% change. The stock currently has a Zacks Rank #3 (Hold), indicating that it could perform in line with the broader market in the near term.\n\nWant the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report\nAdaptive Biotechnologies Corporation (ADPT) : Free Stock Analysis Report\nTo read this article on Zacks.com click here.\nZacks Investment Research","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.3","shortVersion":"4.29.3","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2481193800"}